FDA lists marketing claims it calls deceptive for compounded drugs, including GLP-1s

FDA has posted an updated guidance page aimed at telehealth companies that advertise compounded medicines, setting out in detail which sales pitches the agency regards as misleading ^[1]. The page covers compounded drugs broadly and names compounded GLP-1 receptor agonists as an example of the products drawing the agency's concern ^[1].

FDA says promotion that misleads patients stops them from making informed decisions about their health, and it states that such advertising breaks federal law ^[1]. The agency said it has issued warning letters to telehealth companies over these concerns and points readers to its warning letter database, where a search for "telehealth" turns them up ^[1]. The page does not identify the companies, give a count of the letters, or describe any penalties. Those details have not been disclosed.

The five claims FDA objects to

The updated page lists these practices:

• Website branding that wrongly suggests the telehealth company itself is the compounding pharmacy ^[1].
• Presenting a compounded drug as a generic equivalent of an FDA-approved product, or as the same as one. FDA notes that generic drugs win approval before they are sold, while compounded drugs do not ^[1].
• Saying a compounded drug carries FDA approval, or has been evaluated for safety and effectiveness. Compounded drugs are not reviewed for safety, effectiveness or quality before marketing, according to the page ^[1].
• Calling a compounded drug clinically proven to deliver the same result as an FDA-approved drug ^[1].
• Saying the drug came from an FDA-approved or FDA-licensed pharmacy or outsourcing facility. No facility holds FDA approval or a license from the agency, the page states ^[1].

FDA says it keeps watch over promotional materials and will keep acting to shield patients from misleading pitches by telehealth companies ^[1].

Why it matters for patients

The distinction the page draws is regulatory, not cosmetic. Drugs FDA has approved went through agency review before reaching the market. Compounded versions are mixed by pharmacies or outsourcing facilities and are not FDA-approved, and the agency does not check them for safety, effectiveness or quality ahead of sale ^[1]. That is the basis for treating words like "generic," "FDA-approved" and "clinically proven" as misleading when they are attached to a compounded product ^[1].

One phrase that has shown up in marketing is ruled out altogether: there is no such thing as an FDA-approved or FDA-licensed pharmacy or outsourcing facility, because the agency does not approve or license any facility ^[1].

The page does not take up price, insurance coverage, shipping, or whether a compounded product suits any particular patient. It also does not say how widespread misleading promotion is, or whether the update will be followed by new enforcement. Those points have not been reported.

What happens next

FDA describes no new deadline, rule change or named enforcement step tied to the refreshed page, and no timeline for further action has been reported ^[1]. The agency says only that it will continue taking actions against misleading claims by telehealth companies ^[1]. Readers who want to see past enforcement can search the agency's warning letter database using the term "telehealth," which the page recommends ^[1].